MDM2 and chronic myelogenous leukemia, BCR-ABL1 positive: We found that, unlike the selective MDM2 antagonist Nutlin-3 that was not active in K562 and K562G cells, JNJ-165 showed a strong activity against all tested cell lines containing mutation p53 and primary CML cells.